vs
OCTAVE SPECIALTY GROUP INC（OSG）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
OCTAVE SPECIALTY GROUP INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$66.9M vs $35.5M），OCTAVE SPECIALTY GROUP INC净利率更高（-73.8% vs -304.2%，领先230.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 2.6%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 16.2%）
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
OSG vs RXRX — 直观对比
营收规模更大
OSG
是对方的1.9倍
$35.5M
营收增速更快
RXRX
高出679.2%
2.6%
净利率更高
OSG
高出230.5%
-304.2%
两年增速更快
RXRX
近两年复合增速
16.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.9M | $35.5M |
| 净利润 | $-29.7M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -76.7% | -304.8% |
| 净利率 | -73.8% | -304.2% |
| 营收同比 | 2.6% | 681.7% |
| 净利润同比 | -41.7% | 39.6% |
| 每股收益（稀释后） | $-0.82 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OSGRXRX
| Q4 25 | $66.9M | $35.5M | ||
| Q3 25 | $66.6M | $5.2M | ||
| Q2 25 | $55.0M | $19.2M | ||
| Q1 25 | $62.8M | $14.7M | ||
| Q4 24 | $65.2M | $4.5M | ||
| Q3 24 | $70.0M | $26.1M | ||
| Q2 24 | $51.0M | $14.4M | ||
| Q1 24 | $49.6M | $13.8M |
净利润OSGRXRX
| Q4 25 | $-29.7M | $-108.1M | ||
| Q3 25 | $-112.6M | $-162.3M | ||
| Q2 25 | $-72.7M | $-171.9M | ||
| Q1 25 | $-44.7M | $-202.5M | ||
| Q4 24 | $-20.9M | $-178.9M | ||
| Q3 24 | $-27.5M | $-95.8M | ||
| Q2 24 | $-750.0K | $-97.5M | ||
| Q1 24 | $20.8M | $-91.4M |
毛利率OSGRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率OSGRXRX
| Q4 25 | -76.7% | -304.8% | ||
| Q3 25 | -48.2% | -3327.6% | ||
| Q2 25 | -41.8% | -916.8% | ||
| Q1 25 | -24.1% | -1297.9% | ||
| Q4 24 | -55.5% | -4042.4% | ||
| Q3 24 | -29.7% | -377.1% | ||
| Q2 24 | -28.9% | -697.4% | ||
| Q1 24 | -6.5% | -698.4% |
净利率OSGRXRX
| Q4 25 | -73.8% | -304.2% | ||
| Q3 25 | -169.1% | -3135.3% | ||
| Q2 25 | -132.3% | -894.2% | ||
| Q1 25 | -71.3% | -1373.3% | ||
| Q4 24 | -55.1% | -3935.5% | ||
| Q3 24 | -39.3% | -367.5% | ||
| Q2 24 | -1.5% | -676.6% | ||
| Q1 24 | 41.9% | -662.4% |
每股收益（稀释后）OSGRXRX
| Q4 25 | $-0.82 | $-0.17 | ||
| Q3 25 | $-2.35 | $-0.36 | ||
| Q2 25 | $-1.54 | $-0.41 | ||
| Q1 25 | $-1.22 | $-0.50 | ||
| Q4 24 | $-11.75 | $-0.56 | ||
| Q3 24 | $-0.63 | $-0.34 | ||
| Q2 24 | $-0.02 | $-0.40 | ||
| Q1 24 | $0.44 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.4M | $743.3M |
| 总债务越低越好 | $117.6M | $9.6M |
| 股东权益账面价值 | $715.8M | $1.1B |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.16× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资OSGRXRX
| Q4 25 | $146.4M | $743.3M | ||
| Q3 25 | $27.5M | $659.8M | ||
| Q2 25 | $22.5M | $525.1M | ||
| Q1 25 | $34.1M | $500.5M | ||
| Q4 24 | $157.2M | $594.4M | ||
| Q3 24 | $40.8M | $427.6M | ||
| Q2 24 | $14.6M | $474.3M | ||
| Q1 24 | $13.8M | $296.3M |
总债务OSGRXRX
| Q4 25 | $117.6M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $0 | $19.0M | ||
| Q3 24 | $518.0M | $20.5M | ||
| Q2 24 | $515.0M | $22.9M | ||
| Q1 24 | $512.0M | — |
股东权益OSGRXRX
| Q4 25 | $715.8M | $1.1B | ||
| Q3 25 | $843.4M | $1.0B | ||
| Q2 25 | $859.8M | $919.1M | ||
| Q1 25 | $852.2M | $933.9M | ||
| Q4 24 | $798.4M | $1.0B | ||
| Q3 24 | $1.5B | $524.6M | ||
| Q2 24 | $1.4B | $584.4M | ||
| Q1 24 | $1.4B | $401.2M |
总资产OSGRXRX
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $8.5B | $1.3B | ||
| Q1 25 | $8.3B | $1.3B | ||
| Q4 24 | $8.1B | $1.4B | ||
| Q3 24 | $9.3B | $726.5M | ||
| Q2 24 | $8.2B | $775.9M | ||
| Q1 24 | $8.4B | $557.8M |
负债/权益比OSGRXRX
| Q4 25 | 0.16× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.00× | 0.02× | ||
| Q3 24 | 0.35× | 0.04× | ||
| Q2 24 | 0.38× | 0.04× | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流OSGRXRX
| Q4 25 | $-52.3M | $-46.1M | ||
| Q3 25 | $-41.2M | $-117.4M | ||
| Q2 25 | $2.1M | $-76.4M | ||
| Q1 25 | $-12.6M | $-132.0M | ||
| Q4 24 | $762.0K | $-115.4M | ||
| Q3 24 | $48.9M | $-59.2M | ||
| Q2 24 | $20.4M | $-82.2M | ||
| Q1 24 | $7.1M | $-102.3M |
自由现金流OSGRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率OSGRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度OSGRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率OSGRXRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OSG
| Other | $28.7M | 43% |
| Specialty Property Casualty Program | $23.1M | 34% |
| Accident Health | $9.6M | 14% |
| Specialty Automobile | $3.1M | 5% |
| Niche Specialty Risks | $2.4M | 4% |
RXRX
暂无分部数据
